Related Experiment Video
Updated: Aug 5, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Live Respiratory Syncytial Virus Vaccine D46/cp/ΔM2-2 Is Overattenuated in RSV-Seronegative Children
Ruth A Karron1, Suzanne Woods1, Kimberli Wanionek1
1Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract:
The intranasal respiratory syncytial virus (RSV) vaccine D46/cp/ΔM2-2 is attenuated by deletion of the RSV RNA synthesis factor M2-2 and 5 cold-passage amino acid mutations. D46/cp/ΔM2-2 was safe but overattenuated in 12- to 59-month-old RSV-seropositive children (dose: 106 plaque-forming units [PFU]) and 6- to 24-month-old RSV-seronegative children (dose: 105 PFU). Clinical Trials Registration. ClinicalTrials.gov Number . NCT02601612.
More Related Videos
Related Concept Videos
Respiratory Syncytial Virus Disease
Poliomyelitis
Chickenpox
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

